Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema drug Enbumyst, ...

A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, ...

Looking to clarify its expectations on manufacturer responses following inspections, the FDA earlier this year unveiled, for ...

Four years after gaining FDA approval for Auvelity to treat major depressive disorder (MDD), Axsome Therapeutics has tacked ...

Unionized workers at fast-growing South Korean CDMO Samsung Biologics kicked off a planned general strike on Friday, ...

Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. | Sun ...

It’s a pivotal year for RNA therapeutics pioneer Ionis Pharmaceuticals.  | Fierce's Angus Liu speaks with Ionis CEO Brett ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...

Boston-based Verastem has launched its “Reimagine” campaign to encourage healthcare professionals (HCPs) and patients to ...

The FDA has reprimanded Bayer for the “attention-grabbing visuals” and “frequent scene changes” in ads for the company’s ...

As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at ...

Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos ...